[Mechanism of development and principles of treatment of malignant arterial hypertension].
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000743:Anemia, Hemolytic / Q000150:complications; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D000242:Cyclic AMP / Q000378:metabolism; D005174:Factor XII / Q000378:metabolism; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage; D006974:Hypertension, Malignant / Q000188:drug therapy / Q000209:etiology*; D007741:Labetalol / Q000008:administration & dosage; D010974:Platelet Aggregation; D011460:Prostaglandins F / Q000097:blood; D011817:Rabbits; D051381:Rats; D012084:Renin-Angiotensin System; D013925:Thromboplastin / Q000378:metabolism; D014667:Vasopressins / Q000097:blood; D014883:Water-Electrolyte Imbalance / Q000150:complications
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D011460:Prostaglandins F; D014667:Vasopressins; D006830:Hydralazine; D005174:Factor XII; D013925:Thromboplastin; D000242:Cyclic AMP; D007741:Labetalol
Mekhanizmy razvitiia i printsipy terapii zlokachestvennoĭ arterial'noĭ gipertenzii.